This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDYG
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
by Zacks Equity Research
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
by Zacks Equity Research
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.
Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in operating expenses.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?